406 related articles for article (PubMed ID: 34745101)
1. International Prognostic Index-Based Immune Prognostic Model for Diffuse Large B-Cell Lymphoma.
Mu S; Shi D; Ai L; Fan F; Peng F; Sun C; Hu Y
Front Immunol; 2021; 12():732006. PubMed ID: 34745101
[TBL] [Abstract][Full Text] [Related]
2. Transcriptome profiling reveals an integrated mRNA-lncRNA signature with predictive value for long-term survival in diffuse large B-cell lymphoma.
Gao Q; Li Z; Meng L; Ma J; Xi Y; Wang T
Aging (Albany NY); 2020 Nov; 12(22):23275-23295. PubMed ID: 33221755
[TBL] [Abstract][Full Text] [Related]
3. Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study.
Keane C; Vari F; Hertzberg M; Cao KA; Green MR; Han E; Seymour JF; Hicks RJ; Gill D; Crooks P; Gould C; Jones K; Griffiths LR; Talaulikar D; Jain S; Tobin J; Gandhi MK
Lancet Haematol; 2015 Oct; 2(10):e445-55. PubMed ID: 26686046
[TBL] [Abstract][Full Text] [Related]
4. A prognostic immune risk score for diffuse large B-cell lymphoma.
Ma SY; Tian XP; Cai J; Su N; Fang Y; Zhang YC; Wang JN; Peter Gale R; Cai QQ
Br J Haematol; 2021 Jul; 194(1):111-119. PubMed ID: 33942291
[TBL] [Abstract][Full Text] [Related]
5. Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment.
Alizadeh AA; Gentles AJ; Alencar AJ; Liu CL; Kohrt HE; Houot R; Goldstein MJ; Zhao S; Natkunam Y; Advani RH; Gascoyne RD; Briones J; Tibshirani RJ; Myklebust JH; Plevritis SK; Lossos IS; Levy R
Blood; 2011 Aug; 118(5):1350-8. PubMed ID: 21670469
[TBL] [Abstract][Full Text] [Related]
6. An Immune-Related Prognostic Classifier Is Associated with Diffuse Large B Cell Lymphoma Microenvironment.
Liang XJ; Fu RY; Wang HN; Yang J; Yao N; Liu XD; Wang L
J Immunol Res; 2021; 2021():5564568. PubMed ID: 34212052
[TBL] [Abstract][Full Text] [Related]
7. Mutational, immune microenvironment, and clinicopathological profiles of diffuse large B-cell lymphoma and follicular lymphoma with BCL6 rearrangement.
Carreras J; Ikoma H; Kikuti YY; Miyaoka M; Hiraiwa S; Tomita S; Kondo Y; Ito A; Nagase S; Miura H; Kawada H; Roncador G; Campo E; Hamoudi R; Nakamura N
Virchows Arch; 2024 Apr; 484(4):657-676. PubMed ID: 38462571
[TBL] [Abstract][Full Text] [Related]
8. Identification of molecular subtypes and a novel prognostic model of diffuse large B-cell lymphoma based on a metabolism-associated gene signature.
He J; Chen Z; Xue Q; Sun P; Wang Y; Zhu C; Shi W
J Transl Med; 2022 Apr; 20(1):186. PubMed ID: 35468826
[TBL] [Abstract][Full Text] [Related]
9. Assessment of CD37 B-cell antigen and cell of origin significantly improves risk prediction in diffuse large B-cell lymphoma.
Xu-Monette ZY; Li L; Byrd JC; Jabbar KJ; Manyam GC; Maria de Winde C; van den Brand M; Tzankov A; Visco C; Wang J; Dybkaer K; Chiu A; Orazi A; Zu Y; Bhagat G; Richards KL; Hsi ED; Choi WW; Huh J; Ponzoni M; Ferreri AJ; Møller MB; Parsons BM; Winter JN; Wang M; Hagemeister FB; Piris MA; Han van Krieken J; Medeiros LJ; Li Y; van Spriel AB; Young KH
Blood; 2016 Dec; 128(26):3083-3100. PubMed ID: 27760757
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Nomogram for Overall Survival in Patients with Diffuse Large B-Cell Lymphoma.
Han Y; Yang J; Liu P; He X; Zhang C; Zhou S; Zhou L; Qin Y; Song Y; Sun Y; Shi Y
Oncologist; 2019 Nov; 24(11):e1251-e1261. PubMed ID: 30952824
[TBL] [Abstract][Full Text] [Related]
11. A new prognostic model using the NCCN-IPI and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma.
Go SI; Park S; Kim JH; Kim HR; Kim M; Moon K; Seo J; Lee GW
Tumori; 2018 Aug; 104(4):292-299. PubMed ID: 29737944
[TBL] [Abstract][Full Text] [Related]
12. The importance of Myd88 L265P mutation, clinical and immunohistochemical prognostic factors for the survival of patients with diffuse large B-cell non-Hodgkin lymphoma treated by immunochemotherapy in southeast Serbia.
Tadic L; Marjanovic G; Macukanovic-Golubovic L; Krstic M; Jevtovic-Stoimenov T; Kostov M; Smelcerovic Z; Stojanovic M
J BUON; 2016; 21(5):1259-1267. PubMed ID: 27837631
[TBL] [Abstract][Full Text] [Related]
13. Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies.
Xu-Monette ZY; Li J; Xia Y; Crossley B; Bremel RD; Miao Y; Xiao M; Snyder T; Manyam GC; Tan X; Zhang H; Visco C; Tzankov A; Dybkaer K; Bhagat G; Tam W; You H; Hsi ED; van Krieken JH; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; Winter JN; Medeiros JT; Xu B; Li Y; Kirsch I; Young KH
J Immunother Cancer; 2019 Oct; 7(1):272. PubMed ID: 31640780
[TBL] [Abstract][Full Text] [Related]
14. Expression of N
Xie Z; Li M; Hong H; Xu Q; He Z; Peng Z
Bioengineered; 2021 Dec; 12(1):6115-6133. PubMed ID: 34482808
[TBL] [Abstract][Full Text] [Related]
15. A novel lipid metabolism-based risk model associated with immunosuppressive mechanisms in diffuse large B-cell lymphoma.
Zhang Z; Zhao C; Yang S; Lu W; Shi J
Lipids Health Dis; 2024 Jan; 23(1):20. PubMed ID: 38254162
[TBL] [Abstract][Full Text] [Related]
16. Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma.
Chen W; Liang W; He Y; Liu C; Chen H; Lv P; Yao Y; Zhou H
Med Oncol; 2022 Jan; 39(4):44. PubMed ID: 35092504
[TBL] [Abstract][Full Text] [Related]
17. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
[TBL] [Abstract][Full Text] [Related]
18. Construction of a risk score prognosis model based on hepatocellular carcinoma microenvironment.
Zhang FP; Huang YP; Luo WX; Deng WY; Liu CQ; Xu LB; Liu C
World J Gastroenterol; 2020 Jan; 26(2):134-153. PubMed ID: 31969776
[TBL] [Abstract][Full Text] [Related]
19. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
[TBL] [Abstract][Full Text] [Related]
20. Red blood cell distribution width and platelet counts are independent prognostic factors and improve the predictive ability of IPI score in diffuse large B-cell lymphoma patients.
Li M; Xia H; Zheng H; Li Y; Liu J; Hu L; Li J; Ding Y; Pu L; Gui Q; Zheng Y; Zhai Z; Xiong S
BMC Cancer; 2019 Nov; 19(1):1084. PubMed ID: 31711453
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
